BBIO

BridgeBioC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

Current thesis

Positive pivotal readouts and favorable regulatory/partnering outcomes trigger re-rating toward analyst highs.

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +25.9.

What can break

Clinical failure or missed endpoints for key programs

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $85.79 · Bull $115.50 · Bear $42.63

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-01-19 • Model: RankAlpha Sentiment AI

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net —

Target $107.13

Why

Momentum75 · Δ7d +25.9

Value41 · Δ7d -0.1

Sentiment48 · Δ7d +1.8

So what

Balanced signals. Wait for confirmation before sizing up.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

+25.9

Δ21d

+51.9

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+1.8

Δ21d

-17.8

Why this grade

Composite grade C. Momentum 75.5 / Value 41.1 / Sentiment 48.1

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$15.95B

Beta

1.13

Shares Out

196.04M

P/E (TTM) · Derived

-21.5

P/S (TTM)

39.99

P/FCF (TTM) · Derived

-35.31

Rev YoY

+66.8%

EPS YoY

-4.3%

Gross Margin

+94.7%

Op Margin

-178.4%

Net Debt

$2.14B

Current Ratio

1.52

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology